[1]

Godfrey DI, Kronenberg M. 2004. Going both ways: immune regulation via CD1d-dependent NKT cells. The Journal of Clinical Investigation 114:1379−1388

doi: 10.1172/JCI200423594
[2]

Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, et al. 2011. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nature Immunology 12:966−974

doi: 10.1038/ni.2096
[3]

Berzins SP, Smyth MJ, Baxter AG. 2011. Presumed guilty: natural killer T cell defects and human disease. Nature Reviews Immunology 11:131−142

doi: 10.1038/nri2904
[4]

Courtney AN, Tian G, Metelitsa LS. 2023. Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood 141:869−876

doi: 10.1182/blood.2022016201
[5]

Hammond TC, Purbhoo MA, Kadel S, Ritz J, Nikiforow S, et al. 2024. A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome. Nature Communications 15:974

doi: 10.1038/s41467-024-44905-z
[6]

Garmezy B, Grossman JE, Buell J, Favano T, Stebbing J, et al. 2025. Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor. Oncogene 44:2792−2795

doi: 10.1038/s41388-025-03491-0
[7]

Hadfield MJ, Safran H, Purbhoo MA, Grossman JE, Buell JS, et al. 2024. Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT). Oncogene 43:758−762

doi: 10.1038/s41388-024-02948-y
[8]

van der Vliet HJJ, von Blomberg BME, Hazenberg MD, Nishi N, Otto SA, et al. 2002. Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. The Journal of Immunology 168:1490−1495

doi: 10.4049/jimmunol.168.3.1490
[9]

Juno JA, Keynan Y, Fowke KR. 2012. Invariant NKT cells: regulation and function during viral infection. PLoS Pathogens 8:e1002838

doi: 10.1371/journal.ppat.1002838
[10]

Rajashekar V, Stern L, Almeida CF, Slobedman B, Abendroth A. 2024. The surveillance of viral infections by the unconventional Type I NKT cell. Frontiers in Immunology 15:1472854

doi: 10.3389/fimmu.2024.1472854
[11]

Lu H, Liu Z, Deng X, Chen S, Zhou R, et al. 2023. Potent NKT cell ligands overcome SARS-CoV-2 immune evasion to mitigate viral pathogenesis in mouse models. PLoS Pathogens 19:e1011240

doi: 10.1371/journal.ppat.1011240
[12]

Paul S, Chhatar S, Mishra A, Lal G. 2019. Natural killer T cell activation increases iNOS+CD206- M1 macrophage and controls the growth of solid tumor. Journal for Immunotherapy of Cancer 7:208

doi: 10.1186/s40425-019-0697-7
[13]

Salio M, Silk JD, Jones EY, Cerundolo V. 2014. Biology of CD1- and MR1-restricted T cells. Annual Review of Immunology 32:323−366

doi: 10.1146/annurev-immunol-032713-120243
[14]

Cortesi F, Delfanti G, Grilli A, Calcinotto A, Gorini F, et al. 2018. Bimodal CD40/fas-dependent crosstalk between iNKT cells and tumor-associated macrophages impairs prostate cancer progression. Cell Reports 22:3006−3020

doi: 10.1016/j.celrep.2018.02.058
[15]

Li YR, Zhu Y, Halladay T, Yang L. 2025. In vivo CAR engineering for immunotherapy. Nature Reviews Immunology 25:725−744

doi: 10.1038/s41577-025-01174-1
[16]

Han X, Liao R, Li X, Zhang C, Huo S, et al. 2025. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies. Signal Transduction and Targeted Therapy 10:262

doi: 10.1038/s41392-025-02313-9
[17]

Zhou X, Wang Y, Dou Z, Delfanti G, Tsahouridis O, et al. 2024. CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. Nature Cancer 5:1607−1621

doi: 10.1038/s43018-024-00830-0
[18]

Berrien-Elliott MM, Jacobs MT, Fehniger TA. 2023. Allogeneic natural killer cell therapy. Blood 141:856−868

doi: 10.1182/blood.2022016200
[19]

Myers JA, Miller JS. 2021. Exploring the NK cell platform for cancer immunotherapy. Nature Reviews Clinical Oncology 18:85−100

doi: 10.1038/s41571-020-0426-7